Ultime notizie per Instil Bio (NASDAQ:TIL) Azioni

Instil Bio

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Instil Bio Inc

Till Capital Corp

Interface Inc

Listed Funds Trust Teucrium Agricultural Strategy No K-1 ETF

FlexShares Mornigstar US Market Factors Tilt Index Fund ETF

Shares of chipmaker Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are most likely poised for a reversal as its candlesticks show a rare pattern despite a double downgrade from HSBC on Jan. 8.
What Happened: The semiconductor stock&#8217;s candlestick chart shows a unique &#8216;Bullish Stick Sandwich&#8217; pattern, a technical trading formation suggesting a potential price reversal upwards.
This pattern typically consists of three consecutive candlesticks visually resembling a sandwich on a price chart, as highlighted in the following chart by <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013947/AMD-Candle-stick-1024x504.png" alt="" class="wp-image-733830" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013947/AMD-Candle-stick-1024x504.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013947/AMD-Candle-stick-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013947/AMD-Candle-stick-768x378.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013947/AMD-Candle-stick-1536x756.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013947/AMD-Candle-stick.png 1822w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
A bullish stock sandwich pattern emerges when a bullish candlestick is sandwiched between two bearish ones. This signals potential buying strength amidst a bearish trend.
A larger middle candle strengthens the signal, however, it could also indicate temporary buyer dominance. Confirmation of a reversal comes from subsequent bullish candlesticks, ideally breaking above the prior bearish highs.
The founder of Rock Trading Group, John, said in an <a href="https://x.com/The_RockTrading/status/1877858783415636149">X post</a>, &#8220;Call me nuts I believe $AMD could outperform $NVDA this year,&#8221; sharing the occurrence of the aforementioned pattern. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24AMD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMD</a> <a href="https://t.co/5wGRglPICM">pic.twitter.com/5wGRglPICM</a>
&mdash; John @ The Rock Trading Co. (@The_RockTrading) <a href="https://twitter.com/The_RockTrading/status/1879290712015139027?ref_src=twsrc%5Etfw">January 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Furthermore, the technical analysis of daily moving averages shows a weaker picture of the stock.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42681797/should-you-buy-or-sell-this-nvidia-rival-analysts-weigh-in-as-technicals-signal-a-downtrend">AMD&#8217;s shares</a> closed at $116.09 apiece on Tuesday and it was below its eight-day simple moving average of $121.77 and its 20-day average of $122.83 apiece.
The 50 and 200-day simple moving averages were also above the share price at $132.86 and $151.11, respectively, suggesting a bearish trend.
On the other hand, the relative strength index of 35.51 suggested that the stock could be moderately oversold but still in the neutral zone.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/01/42967576/meta-investors-push-mark-zuckerberg-to-replace-72b-cash-with-bitcoin-to-combat-inflation-heres-what-it-means-for-investors">Meta Investors Push Mark Zuckerberg To Replace $72B Cash With Bitcoin To Combat Inflation: Here&#8217;s What It Means For Investors </a>
Why It Matters: HSBC&#8217;s Frank Lee, downgraded the stock from &#8220;Buy&#8221; to &#8220;Reduce&#8221; last week with a 45% reduction in its share price target from $200 to $110 per share.
According to a research note, as <a href="https://www.gurufocus.com/news/2650529/amd-shares-slide-as-hsbc-downgrades-stock-over-nvidia-concerns-absci-collaboration-announced">reported </a>by GuruFocus, he expects reduced demand for AMD&#8217;s MI325 GPU and supply issues with high-bandwidth memory from Samsung. Lee suggested that AMD could face a competitive disadvantage in AI rack solutions until the arrival of its MI400 series, expected in late 2025 or early 2026.
In a research note published Tuesday, Jan. 14, Loop Capital initiated coverage of AMD with a &#8220;Buy&#8221; rating and a price target of $175. The firm expressed confidence in AMD&#8217;s future growth prospects, particularly in the accelerated computing market, <a href="https://in.investing.com/news/stock-market-news/amd-initiated-with-a-buy-rating-at-loop-capital-4612142">reported </a>Investing.com.
Loop Capital highlighted AMD&#8217;s potential to gain significant market share in both the data center and PC segments. The firm believes that AMD&#8217;s stock, which has underperformed the PHLX Semiconductor Sector index in 2024, is currently undervalued compared to its competitors.
About 31 <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">analysts tracked by Benzinga</a> have a consensus &#8220;Buy&#8221; rating with an average target price of $184.53 on AMD stock. Keybanc, Loop Capital, and Wells Fargo are among the three most recent analyst ratings, and their average price target stands at $163.33, implying a 41.01% upside.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/AMD/analyst-ratings"><img loading="lazy" decoding="async" width="940" height="352" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013801/AMD-ANR-ANR.png" alt="" class="wp-image-733826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013801/AMD-ANR-ANR.png 940w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013801/AMD-ANR-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15013801/AMD-ANR-ANR-768x288.png 768w" sizes="(max-width: 940px) 100vw, 940px" /></a></figure>
Price Action: Shares of AMD gained over 0.2% in pre-market hours on Wednesday. The stock has declined by 8.37% over the past month and 26.87% over the last year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42967497/charlie-mungers-defense-of-active-investing-resurfaces-amid-etf-boom-life-is-more-than-passive-wealth-accumulation">Charlie Munger&#8217;s Defense Of Active Investing Resurfaces Amid ETF Boom: &#8220;Life Is More Than Passive Wealth Accumulation&#8221;</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Equities

News

Downgrades

Price Target

Technicals

Initiation

Markets

Analyst Ratings

Trading Ideas

AMD Shares Hint At A Reversal As Charts Show Bullish Stick Sandwich Following A Double Downgrade From HSBC

The Bank Of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) shares are trading higher in the premarket session on Wednesday after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42997457/bny-reports-fourth-quarter-2024-results" rel="noreferrer noopener">fourth-quarter 2024 results</a>.
The finance behemoth reported fourth-quarter adjusted earnings per share of $1.72 (+33% YoY), <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the street view of $1.56.</a>
Quarterly revenue of $4.847 billion, an increase of 11% year-over-year, surpassed the analyst consensus of $4.653 billion.
Fee revenue in the quarter grew 9% YoY to $3.513 billion. Net interest income rose 8% YoY, reflecting higher portfolio yields and balance growth, offset by deposit mix shifts.
Noninterest expense fell 16% YoY, driven by FDIC adjustments, savings, and lower severance costs, partially offset by merit increases and investments. Excluding notable items, noninterest&nbsp;expenses rose 2%.
The provision for credit losses totaled $20 million for the quarter, mainly due to reserve increases tied to commercial real estate exposure.
The Bank of New York Mellon reported average deposits of $286 billion, which increased 5% year over year and declined 1% sequentially.
The company stated that its fourth-quarter tier 1 leverage ratio of 5.7% decreased 23 bps year over year and 29 bps sequentially. Adjusted pre-tax operating margin totaled 34% (vs. 29% a year ago).
At December 31, 2024, CET1 capital was $18.8 billion and Tier 1 capital was $23.0 billion, both down from September 30, 2024, due to lower comprehensive income and capital returns, partially offset by earnings.
BNY declared a common stock dividend of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42997483/bny-declares-dividends" rel="noreferrer noopener">$0.47 per share</a>, payable on February 7, 2025, to shareholders of record as of the close of business on January 27, 2025.
The bank returned $1.1 billion to common shareholders, including $349 million in dividends and $750 million in share repurchases, achieving a total payout ratio of 102% for full-year 2024.
&#8220;We launched a new commercial coverage model, developed new products and solutions for our clients, completed a brand refresh, announced and closed our first acquisition in several years, and commenced the phased transition to our strategic platforms operating model. We also continued to invest in our culture and attracted top talent to further strengthen our team,&#8221; commented President and Chief Executive Officer Robin Vince.
Fiscal 2024 revenue rose 5% YoY, with fee revenue up 6% from higher market values, new business, and client activity.
FY24 Net interest income fell 1% due to deposit mix changes, offset by higher yields and balance growth. Credit loss provisions hit $70 million, driven by real estate reserves and forecasts. Noninterest expenses dropped 4% from FDIC adjustments and savings.
Price Action: BK shares are trading higher by 2.57% to $77.89 premarket at the last check Wednesday.
Photo via Shutterstock.

Earnings

Dividends

Movers

BNY Q4 Earnings: Higher Revenue, Lower Costs, And 102% Payout Ratio To Shareholders

Evercore ISI Group analyst James West downgrades Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) from Outperform to In-Line and lowers the price target from $87 to $59.

Evercore ISI Group Downgrades Valaris to In-Line, Lowers Price Target to $59

Wells Fargo CFO Says The Consumer Continues To Be Strong

Cantor Fitzgerald analyst Kristen Kluska reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and maintains $21 price target.

Reiteration

FOLD

Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $21 Price Target

Evercore ISI Group analyst James West downgrades Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) from Outperform to In-Line and lowers the price target from $6 to $5.

Evercore ISI Group Downgrades Transocean to In-Line, Lowers Price Target to $5

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $80 to $76.

PTCT

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76

Canaccord Genuity analyst Austin Moeller maintains Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) with a Buy and maintains $6 price target.

BAER

Canaccord Genuity Maintains Buy on Bridger Aerospace Gr, Maintains $6 Price Target

Cantor Fitzgerald analyst Brett Knoblauch maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Overweight and lowers the price target from $15 to $14.

APLD

Cantor Fitzgerald Maintains Overweight on Applied Digital, Lowers Price Target to $14

Evercore ISI Group analyst James West downgrades Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) from Outperform to In-Line and lowers the price target from $64 to $41.

Evercore ISI Group Downgrades Noble Corp to In-Line, Lowers Price Target to $41

OS Therapies reiterates clinical and regulatory path in recurrent, fully respected osteosarcoma with lung metastases, an indication with no currently approved treatments.
 &nbsp;

OSTX

OS Therapies Says Phase 2b Clinical Trial Of OST-HER2 Achieves Primary Endpoint With Statistical Significance In Prevention Of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Interview

BlackRock CEO Larry Fink Says Don't Believe You'll See BlackRock In The Market Buying Whole Companies

Evercore ISI Group analyst James West downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Outperform to In-Line and lowers the price target from $48 to $39.

Evercore ISI Group Downgrades Helmerich & Payne to In-Line, Lowers Price Target to $39

WIIM

Bank of New York Mellon shares are trading higher following better-than-expected Q4 financial results.

SPRC

SciSparc Says It Is Granted 180-Day Extension Until July 14, 2025, By Nasdaq To Regain Compliance With Minimum Bid Requirement

GS: 3% &#x7C; <a href="https://www.benzinga.com//node/42999133">Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking &amp; Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%</a>
&nbsp;
VCEL: -12% &#x7C; <a href="https://www.benzinga.com//node/42997435">Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.</a>
&nbsp;
COMP: 11% &#x7C; <a href="https://www.benzinga.com//node/42998131">Compass shares are trading higher after the company raised its Q4 and FY24 guidance.</a>

COMP

VCEL

Market-Moving News for January 15th

AVXL

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

Seaport Global analyst Kenneth Zener upgrades KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) from Sell to Neutral.

Upgrades

Seaport Global Upgrades KB Home to Neutral

Prairie expects Average Daily Production: 7,000 – 8,000 barrels of oil equivalent per day (BOEPD), representing a ~300% increase year-over-year.
Prairie plans to actively pursue additional strategic acquisition opportunities, the completion of which will result in an update to guidance to reflect the enhanced scale and value of the Company.

Guidance

PROP

Prairie Operating Expects 2025 Net Income  Of $69M - $102M, Adjusted EBITDA Of $100M - $140M,

Goldman Sachs Total Loans Increased 7% During The Year

17:04 EST Instil Bio (TIL) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Instil Bio files $200M mixed securities shelf

In a report released today, Reni Benjamin from JMP Securities reiterated a Hold rating on Instil Bio (TIL – Research Report). The company's shares ...

Instil Bio (TIL) Gets a Hold from JMP Securities

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of $110.00. Mitc...

Instil Bio Poised for Growth Amid Biopharmaceutical Sector Activity and Strong Financial Position

H.C. Wainwright lowered the firm's price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 report. The ...

Instil Bio price target lowered to $110 from $120 at H.C. Wainwright

Merck to buy rights to Chinese cancer drug for up to $3.3B

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Instil Bio (TIL – Research Report). The associated price target rema...

Strategic Acquisitions and Market Potential Position Instil Bio's SYN-2510 as a Buy with High Growth Prospects

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Instil Bio ( ($TIL) ) has shared an announcement. Instil Bio, Inc., through its subsidiary Complex Therapeutics LLC, has secured an $85.6 million t...

Instil Bio Secures Loan to Refinance Facility

Jefferies upgraded Instil Bio (TIL) to Buy from Hold with a price target of $52, up from $11. Published first on TheFly – the ultimate source for r...

Instil Bio upgraded to Buy from Hold at Jefferies

Instil Bio (TIL)y announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceuticals. ImmuneOnco announced...

Instil Bio announces clinical progress in China for IMM2510/SYN-2510

BNTX

SMMT

Press Releases

General

Instil Bio Announces Strategic Update

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Health Care

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Comments

Instil Bio

Notizie

Ultime notizie per Instil Bio (NASDAQ:TIL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO